Jeffrey Bradley, MD Journal of Thoracic Oncology

Slides:

Advertisements

Similar presentations

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

Advertisements

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

Jeffrey Bradley, MD Journal of Thoracic Oncology

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Lungs on Fire Journal of Thoracic Oncology

Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc.

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

MET-Mutated NSCLC with Major Response to Crizotinib

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Significant Aspirations: Recurrent Pneumonia

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Prognostic Impact of the Findings on Thin-Section Computed Tomography in Patients with Subcentimeter Non–Small Cell Lung Cancer Aritoshi Hattori, MD,

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

Toxicities of Organs at Risk in the Mediastinal and Hilar Regions Following Stereotactic Body Radiotherapy for Centrally Located Lung Tumors Shuichi.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

Ritbune Prakobkit, MD, William Churk-Nam Auyeung, MD

Massive Bronchogenic Cyst

Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with.

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Rubinowitz Ami N. , MD, Moon Marianne , MD, Homer Robert , MD, PhD

Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non–Small-Cell Lung Cancer Shankar Siva, MBBS, FRANZCR, Jason Callahan, BAppSci,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Salvage Operation for Late Recurrence After Stereotactic Body Radiotherapy for Lung Cancer: Two Patients With No Viable Cancer Cells Naohiro Taira, MD,

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural.

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters John J. Cuaron, MD, Ellen D. Yorke, PhD, Amanda Foster, BA, Meier Hsu, MS,

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Nicholas Trakul, MD, PhD, Jeremy P

Multiple Pulmonary Nodules in an Elderly Woman

Salvage Lung Resection for Non-small Cell Lung Cancer After Stereotactic Body Radiotherapy in Initially Operable Patients Fengshi Chen, MD, PhD, Yukinori.

Nicholas W. Choong, MD, Robert S. Hellman, MD

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

International Thymic Malignancies Interest Group: A Way Forward

Recurrent Primary Synovial Sarcoma of the Chest Wall

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Metastatic Lung Cancer to the Pancreas

Collaterals Journal of Thoracic Oncology

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Cristiano Rampinelli, MD, Vittoria Vecchi, MD, Massimo Bellomi, MD

Journal of Thoracic Oncology

Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib Amber B. Koehler, PA-C, MS Mayo.

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

David Garfield, MD Journal of Thoracic Oncology

Popcorn in the Lung Journal of Thoracic Oncology

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Volume 156, Issue 2, Pages e41-e45 (August 2019)

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Farhood Farjah, MD, MPH, David R. Flum, MD, MPH, Scott D

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Radiographic Response and Clinical Toxicity Following SBRT for Stage I Lung Cancer Jeffrey Bradley, MD Journal of Thoracic Oncology Volume 2, Issue 7, Pages S118-S124 (July 2007) DOI: 10.1097/JTO.0b013e318074e50c Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Diffuse consolidation after stereotactic body radiation therapy. This patient received 54 Gy in three fractions to a left upper lobe cancer prescribed to the 85% isodose line. Her follow-up computed tomography (CT) scan obtained 6 weeks following SBRT showed a radiographic response. However, her chest CT at 6 months was concerning for local recurrence. A flurodeoxyglucose positron emission tomography (PET) was obtained to help differentiate between recurrence and fibrosis. The PET reading suggested an inflammatory response but could not rule out recurrence. This patient has been followed for 18 months and is without recurrence. Journal of Thoracic Oncology 2007 2, S118-S124DOI: (10.1097/JTO.0b013e318074e50c) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Patchy consolidation and ground-glass opacity (GGO) after stereotactic body radiation therapy. This patient received 60 Gy in three fractions to a right upper lobe cancer prescribed to the 80% isodose line. His follow-up computed tomography (CT) scan at 6 weeks showed stable disease. CT at 6 months demonstrated an improved response with residual patchy consolidation and GGO. Positron emission tomography (PET) showed no evidence of residual cancer. This patient has been followed for 20 months and is without recurrence. Journal of Thoracic Oncology 2007 2, S118-S124DOI: (10.1097/JTO.0b013e318074e50c) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 No evidence of increasing density. This patient received 54 Gy in three fractions to this right lower lobe cancer prescribed to the 85% isodose line. His follow-up computed tomography scan demonstrated tumor regression followed by a complete radiographic response. This patient remains without evidence of recurrence 36 months following stereotactic body radiation therapy. Journal of Thoracic Oncology 2007 2, S118-S124DOI: (10.1097/JTO.0b013e318074e50c) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Scarlike pattern of radiation fibrosis. This patient received 54 Gy in three fractions to his right lung cancer. Computed tomography (CT) obtained 6 weeks after therapy demonstrated a radiographic response. The CT and positron emission tomography/CT scans obtained 12 months after therapy showed no evidence of recurrent cancer. A scarlike band is seen posterior to the original tumor location with associated volume loss. Journal of Thoracic Oncology 2007 2, S118-S124DOI: (10.1097/JTO.0b013e318074e50c) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions